Page last updated: 2024-12-08

deflazacort

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

deflazacort: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID189821
CHEMBL ID1201891
CHEBI ID135720
SCHEMBL ID4018
MeSH IDM0077553

Synonyms (85)

Synonym
AB01274724-01
CHEMBL1201891
mdl458
dl-458it
deflan
mdl-458
flantadin
l-5458
azacort
oxazacort
calcort
dezacor
2-[(4ar,4bs,5s,6as,6bs,9ar,10as,10bs)-5-hydroxy-4a,6a,8-trimethyl-2-oxo-2,4a,4b,5,6,6a,9a,10,10a,10b,11,12-dodecahydro-6bh-naphtho[2',1':4,5]indeno[1,2-d][1,3]oxazol-6b-yl]-2-oxoethyl acetate
deflazacort (usan/inn)
14484-47-0
D03671
emflaza (tn)
einecs 238-483-7
5'h-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione, 21-(acetyloxy)-11-hydroxy-2'-methyl-, (11beta,16beta)-
(11beta,16beta)-21-(acetyloxy)-11-hydroxy-2'-methyl-5'h-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione
dl-458-it
mdl 458
11beta,21-dihydroxy-2'-methyl-5'betah-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione 21-acetate
5'-beta-h-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione, 11-beta,21-dihydroxy-2'-methyl-, 21-acetate
deflazacortum [inn-latin]
lantadin
deflazacort
CHEBI:135720
emflaza
unii-kr5yz6ae4b
enzocort
deflazacortum
kr5yz6ae4b ,
deflazacort [usan:inn:ban]
cas-14484-47-0
dtxsid9020378 ,
NCGC00255189-01
dtxcid10378
tox21_301415
tox21_112506
deflanil
decortil
cortax
deflazacort [who-dd]
deflazacort [mart.]
deflazacort [usp-rs]
5'h-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione, 21-(acetyloxy)-11-hydroxy-2'-methyl-, (11.beta.,16.beta.)-
11.beta.,21-dihydroxy-2'-methyl-5'.beta.h-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione 21-acetate
deflazacort [orange book]
deflazacort [mi]
deflazacort [usan]
deflazacort [inn]
S1888
AKOS015895199
CCG-220817
HY-13609
SCHEMBL4018
tox21_112506_1
NCGC00263521-01
KS-1158
Q-101371
2-((6ar,6bs,7s,8as,8bs,11ar,12as,12bs)-7-hydroxy-6a,8a,10-trimethyl-4-oxo-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bh-naphtho[2',1':4,5]indeno[1,2-d]oxazol-8b-yl)-2-oxoethyl acetate
D4523
AB01274724_02
mfcd00866106
[2-[(1s,2s,4r,8s,9s,11s,12s,13r)-11-hydroxy-6,9,13-trimethyl-16-oxo-5-oxa-7-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-6,14,17-trien-8-yl]-2-oxoethyl] acetate
deflazacort, united states pharmacopeia (usp) reference standard
deflazacort, >=98% (hplc)
gtpl9477
HMS3714D15
2-((6ar,6bs,7s,8as,8bs,11ar,12as,12bs)-7-hydroxy-6a,8a,10-trimethyl-4-oxo-2,4,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-1h-naphtho[2',1':4,5]indeno[1,2-d]oxazol-8b-yl)-2-oxoethyl acetate
11b,21-dihydroxy-2'-methyl-5'bh-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione 21-acetate
DB11921
BCP08474
Q779118
STL559051
BBL036672
T70289
3-amino-3-(4-chloro-3-nitro-phenyl)-propionicacid
EN300-24137083
2-[(1s,2s,4r,8s,9s,11s,12s,13r)-11-hydroxy-6,9,13-trimethyl-16-oxo-5-oxa-7-azapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-6,14,17-trien-8-yl]-2-oxoethyl acetate
h02ab13
deflazacort (usp-rs)
deflazacort (mart.)
deflazacortum (inn-latin)

Research Excerpts

Overview

Deflazacort (DFZ) is a synthetic corticosteroid characterized by a favourable pharmacokinetic profile, peculiar pharmacodynamic properties and a good safety profile. It is an oxazoline derivative of prednisolone with anti-inflammatory and immunosuppressive activity.

ExcerptReferenceRelevance
"Deflazacort is a synthetic corticosteroid characterized by a favourable pharmacokinetic profile, peculiar pharmacodynamic properties and a good safety profile. "( Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids.
Parente, L, 2017
)
3.34
"Deflazacort (DFZ) is an oxazoline derivative of prednisolone with anti-inflammatory and immunosuppressive activity. "( Isolation and characterization of a degradation product of deflazacort.
Cardoso, SG; Deobald, AM; Eberlin, MN; Paulino, AS; Paulino, N; Rauber, G; Sawaya, AC, 2012
)
2.06
"Deflazacort is a relatively new glucocorticoid with significant immunosuppressant activity and presumably fewer side effects. "( Effects of deflazacort and cortisone on cellular proliferation in the rat thymus.
Carbajo, S; Carbajo-Pérez, E; Chan, JC; Krieg, RJ; Latta, K, 2002
)
2.15
"Deflazacort (DFZ) is a synthetic glucocorticoid claimed to have lesser side effects than prednisone."( Deflazacort induced stronger immunosuppression than expected.
Castellanos-Alvarado, EA; Flores-Marquez, MR; Garcia-Estrada, J; Gonzalez-Castañeda, RE; Gonzalez-Perez, O; Luquin, S; Ramos-Remus, C, 2007
)
2.5
"Deflazacort (DFZ) is a synthetic glucocorticoid that has few adverse effects on glucose and calcium metabolism and fewer deleterious effects on the neuronal population. "( Deflazacort: a glucocorticoid with few metabolic adverse effects but important immunosuppressive activity.
Garcia-Estrada, J; Gonzalez-Perez, O; Luquin, S; Ramos-Remus, C,
)
3.02
"Deflazacort is a new synthetic glucocorticoid which is an oxazoline derivative of prednisolone. "( Comparative study of deflazacort, a new synthetic corticosteroid, and dexamethasone on the synthesis of collagen in different rat bone cell populations and rabbit articular chondrocytes.
Felix, R; Fleisch, H; Guenther, HL, 1984
)
2.03
"Deflazacort is a synthetic glucocorticoid with fewer adverse effects on bone and carbohydrate metabolism than prednisone or beta-methasone. "( Immunosuppressive effects of deflazacort - a new glucocorticoid with bone-sparing and carbohydrate-sparing properties: comparison with prednisone.
Hahn, BH; Muniain, M; Pletscher, LS,
)
1.87
"Deflazacort is a new glucocorticoid which in previous studies was found to be about 0.8 times as potent as prednisone. "( Deflazacort in thrombocytopenia: a comparison with prednisone.
Criscuolo, D; De Laurentis, C; Malagnino, F; Mazzucconi, MG, 1980
)
3.15
"Deflazacort is an inactive prodrug which is converted rapidly to the active metabolite 21-desacetyldeflazacort. "( Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone.
Barth, J; Derendorf, H; Hochhaus, G; Möllmann, H; Rohatagi, S, 1995
)
1.99
"Deflazacort is an oxazoline derivative of cortisone with presumably less serious side effects, but its effects on growth factors are unknown. "( Effects of deflazacort and cortisone on body growth, thymus weight and gene expression of growth-related proteins in the rat.
Chan, JC; Chan, W; Hisano, S; Krieg, RJ; Latta, K, 1994
)
2.12
"Deflazacort (DFC) is a heterocyclic glucocorticoid with anti-inflammatory activity but with decreased side effects. "( Binding of the anti-inflammatory steroid deflazacort to glucocorticoid receptors in brain and peripheral tissues. In vivo and in vitro studies.
Coirini, H; De Nicola, AF; Flores, D; Gonzalez Deniselle, MC; Vega, MC, 1994
)
2
"Deflazacort is a derivative of prednisolone and is currently used in humans."( Chronic effects of corticosteroid oral treatment in rats on blood glucose and serum insulin levels, pancreatic islet morphology, and immunostaining characteristics.
Eyster, RC; Zwicker, GM,
)
0.85
"Deflazacort is a glucocorticoid which has been reported to be relatively "bone-sparing." We compared the effects in oophorectomized sheep of deflazacort and prednisolone on the metabolism of osteocalcin (OC), a marker of osteoblast function."( Effects of prednisolone and deflazacort on osteocalcin metabolism in sheep.
Farrugia, W; Fortune, CL; McDougall, JG; O'Connell, SL; Scoggins, BA; Tresham, J; Wark, JD, 1993
)
1.3
"Deflazacort (DFZ) is a novel glucocorticoid with bone sparing properties, and there have been numerous studies investigating its potency relative to other glucocorticoids. "( Potency ratio--a brief synopsis.
Avioli, LV, 1993
)
1.73
"Deflazacort is an oxazoline derivative of prednisolone with anti-inflammatory and immunosuppressive activity. "( Deflazacort. A review of its pharmacological properties and therapeutic efficacy.
Bryson, HM; Markham, A, 1995
)
3.18
"Deflazacort is an oxazoline compound derived from prednisolone. "( Effects of deflazacort immunosuppression on long-term growth and growth factors after renal transplantation.
Ferraris, JR; Jasper, H; Pasqualini, T; Pennisi, P, 1997
)
2.13
"Deflazacort is an oxazolone compound derived from prednisolone, with similar immunosuppressive action but fewer side effects. "( Effect of therapy with deflazacort on dyslipoproteinemia after pediatric renal transplantation.
Brandi, P; Ferraris, JR; Legal, S; Oyhamburu, J; Pasqualini, T; Sorroche, P, 1998
)
2.05
"Deflazacort (DFZ) is a relatively new glucocorticoid that has been reported to exhibit fewer side-effects than other commonly used corticosteroids. "( Effect of the synthetic glucocorticoid, deflazacort, on body growth, pulsatile secretion of GH and thymolysis in the rat.
Chan, JC; Hisano, S; Krieg, RJ; Latta, K; Veldhuis, JD, 1999
)
2.01
"Deflazacort is an oxazoline compound derived from prednisolone with similar antiinflammatory effects but fewer side effects. "( Effect of therapy with a new glucocorticoid, deflazacort, on linear growth and growth hormone secretion after renal transplantation.
Fainstein Day, P; Ferraris, JR; Granillo, E; Gutman, R; Pasqualini, T; Ramirez, J; Ruiz, S, 1992
)
1.99
"Deflazacort (DFC) is a new glucocorticoid which, when compared with prednisone (PDN), has similar anti-inflammatory actions, but lacks several unwanted side effects on mineral and carbohydrate metabolism. "( Effects of a new heterocyclic glucocorticoid, deflazacort (DFC), on the functions of lymphocytes from patients with rheumatoid arthritis (RA).
Imbimbo, B; Indiveri, F; Piccardo, C; Piovano, P; Scudeletti, M, 1987
)
1.97
"Deflazacort is an oxazoline derivative of prednisolone with documented calcium-sparing properties when compared to prednisone on a weight basis."( Establishment of the relative antiinflammatory potency of deflazacort and prednisone in polymyalgia rheumatica.
Egsmose, C; Jørgensen, S; Krogsgaard, MR; Lund, B, 1987
)
1.24

Effects

Deflazacort (DFZ) has similar immunomodulating effects to other GCs but, by contrast, DFZ produces less hypercalciuria and hyperglycaemia than prednisone and dexamethasone. It has antiinflammatory activity in various laboratory models, such as carrageenin and nystatin oedema.

ExcerptReferenceRelevance
"Deflazacort has shown similar effects to prednisone, but with a less worrying adverse-effect profile."( A comparative study of hydrocortisone versus deflazacort in drug-resistant epilepsy of childhood.
Balestri, P; Berardi, R; Cordelli, D; Farnetani, M; Grosso, S; Mostardini, R, 2008
)
1.33
"Deflazacort has benefitted both cohorts by prolonged ambulation, preserved cardiac and respiratory function, less scoliosis and improved survival."( The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy.
Alman, BA; Biggar, WD; Mayo, AL; McAdam, LC, 2012
)
1.37
"Deflazacort has antiinflammatory activity in various laboratory models, such as carrageenin and nystatin oedema, cotton pellet granuloma, adjuvant arthritis and on liver glycogen storage."( Antiinflammatory activity and other pharmacological properties of 11 beta, 21-dihydroxy-2'-methyl-5' beta H-pregna-1,4 dieno[17,16-d] oxazole 3,20-dione-21-acetate (Deflazacort).
Barone, D; Glässer, A; Restelli, A; Schiatti, P; Selva, D, 1980
)
1.18
"Deflazacort (DFZ) has similar immunomodulating effects to other GCs but, by contrast, DFZ produces less hypercalciuria and hyperglycaemia than prednisone and dexamethasone."( Deflazacort in the treatment of haematologic disorders.
Gobbi, M; Scudeletti, M, 1993
)
2.45
"Deflazacort (DFZ) has been proposed as an alternative drug for immunosuppression after renal transplantation (TX), with fewer side effects than conventional glucocorticoids. "( Experience with deflazacort in children and adolescents after renal transplantation.
Feneberg, R; Klaus, G; Mehls, O; Paschen, C; Schaefer, F; Schärer, K; Wüster, C, 2000
)
2.1
"Deflazacort (DF) has been claimed to be provided with a reduced distribution into the central nervous system, therefore it is conceivable that this glucocorticoid holds a lower inhibitory effect on GH secretion. "( Effect of deflazacort on growth hormone response to insulin tolerance test.
Adami, S; Cominacini, L; Daví, MV; Francia, G; LoCascio, V; Olivieri, M; Rossi, L, 1992
)
2.13

Treatment

Deflazacort may be an effective alternative to prednisone treatment, with fewer adverse effects on levels of calcium and cortisol, in patients with severe inflammatory conditions warranting the use of glucocorticoids. The treatment was well-tolerated in all children with no significant side effects reported.

ExcerptReferenceRelevance
"Deflazacort-treated patients experienced significantly lower functional decline over 48 weeks."( Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.
Cox, DA; Darras, BT; Elfring, G; Landry, J; McDonald, CM; McDonnell, E; Peltz, SW; Sajeev, G; Shieh, PB; Signorovitch, J; Souza, M; Yao, Z, 2020
)
3.44
"Deflazacort treatment resulted in increased NOS-Imu expression in regenerating muscles in a strong and specific correlation with myf5 expression (r=0.95, P<0.01), a marker for muscle repair."( Correlated NOS-Imu and myf5 expression by satellite cells in mdx mouse muscle regeneration during NOS manipulation and deflazacort treatment.
Anderson, JE; Vargas, C, 2003
)
1.25
"Deflazacort treatment started between 4 and 8 years of age."( Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.
Alman, B; Biggar, WD; Comi, LI; Harris, VA; Nigro, G; Palladino, A; Passamano, L; Politano, L; Vajsar, J, 2004
)
2.49
"In deflazacort-treated boys, alendronate had a positive effect on BMD z scores; the effect was greatest when given early in the course of disease."( Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy.
Biggar, WD; Chase, CC; Fielding, LJ; Harris, VA; Hawker, GA; Ridout, R, 2005
)
0.95
"Deflazacort treatment resulted in clinical and radiological improvement within 12 months with no side effects."( Deflazacort treatment in progressive diaphyseal dysplasia (Camurati-Engelmann disease).
Baş, F; Bilir, A; Bundak, R; Darendeliler, F; Günöz, H; Petorak, I; Sadikoğlu, B; Saka, N, 1999
)
2.47
"The treatment with deflazacort was well-tolerated in all children with no significant side effects reported."( Acute and chronic corticosteroid treatment of ten patients with paralytic form of Sydenham's chorea.
Della Giustina, E; Frattini, D; Fusco, C; Pisani, F; Ucchino, V, 2012
)
0.7
"Treatment with deflazacort may be an effective alternative to prednisone treatment, with fewer adverse effects on levels of calcium and cortisol, in patients with severe inflammatory conditions warranting the use of glucocorticoids."( A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders.
Coulton, L; de Broe, M; Doherty, SM; Galloway, J; Gray, RE; Kanis, JA, 1991
)
0.93

Toxicity

Deflazacort (DFZ) is claimed to have fewer adverse bone effects than prednisone (PDN) at doses with equivalent anti-inflammatory activity.

ExcerptReferenceRelevance
"Deflazacort (DFZ) is claimed to have fewer adverse bone effects than prednisone (PDN) at doses with equivalent anti-inflammatory activity (5 mg PDN = 6 mg DFZ)."( The long-term efficacy and safety of two different corticosteroids in chronic sarcoidosis.
Imbimbo, B; Milani, S; Riboldi, A; Rizzato, G; Torresin, A, 1997
)
1.74
"Deflazacort (DFZ) is a synthetic glucocorticoid that has few adverse effects on glucose and calcium metabolism and fewer deleterious effects on the neuronal population."( Deflazacort: a glucocorticoid with few metabolic adverse effects but important immunosuppressive activity.
Garcia-Estrada, J; Gonzalez-Perez, O; Luquin, S; Ramos-Remus, C,
)
3.02
" The most frequent adverse events in all 3 active treatment arms were Cushingoid appearance, erythema, hirsutism, increased weight, headache, and nasopharyngitis."( Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.
Cwik, V; Dubow, JS; Fehlings, DL; Florence, JM; Greenberg, CR; Griggs, RC; King, W; Kissel, JT; Mendell, JR; Meyer, JM; Miller, JP; Moxley, RT; Pandya, S; Pestronk, A; Vanasse, M, 2016
)
0.74
"A 23-item questionnaire (SIDECORT: side effect of corticosteroids) was constructed to assess the perception of these benefits and side effects in a systematic manner."( Development of a New Self-Reporting Instrument Measuring Benefits and Side Effects of Corticosteroids in Duchenne Muscular Dystrophy: Report from a Pilot Study.
Biggar, WD; Hendriksen, JGM; Hendriksen, RGF; Lionarons, JM; McAdam, LC; Vles, JSH,
)
0.13
" Using factor analyses on the side effect items as reported by parents, two underlying factors were found, with the first factor describing cognitive, behavioural and emotional functioning, and the second factor describing physical functioning."( Development of a New Self-Reporting Instrument Measuring Benefits and Side Effects of Corticosteroids in Duchenne Muscular Dystrophy: Report from a Pilot Study.
Biggar, WD; Hendriksen, JGM; Hendriksen, RGF; Lionarons, JM; McAdam, LC; Vles, JSH,
)
0.13

Pharmacokinetics

ExcerptReferenceRelevance
"Due to the short pharmacokinetic half-life of its active metabolite, pharmacodynamic effects of deflazacort are of shorter duration than those of methylprednisolone and prednisolone."( Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone.
Barth, J; Derendorf, H; Hochhaus, G; Möllmann, H; Rohatagi, S, 1995
)
0.77
" Cmax averaged 10."( An investigation of the dose proportionality of deflazacort pharmacokinetics.
Bhargava, VO; Eller, MG; Rao, N; Reynolds, DL; Weir, SJ, 1996
)
0.55
" Serum concentration profiles and pharmacokinetic parameters were similar in patients on hemodialysis, renal transplant recipients and normal children."( Pharmacokinetics of deflazacort in renal transplanted and hemodialyzed children.
Díaz, L; Ferraris, J; Flores, D; Giogieri, S; Krmar, R; Tessler, J, 1998
)
0.62
" The aim of this study is to evaluate the pharmacokinetic properties of 21-OH DFZ in healthy Chinese volunteers after a single and multiple oral administration of DFZ tablets under fed condition."( [Pharmacokinetics of deflazacort tablets in healthy Chinese volunteers].
Ding, L; Ding, W; Li, WB; Lin, HD; Pan, H, 2014
)
0.72

Bioavailability

Deflazacort (DFZ, a prodrug) is well absorbed and rapidly metabolized into the active metabolite 21-hydroxydeflazACort (21-OH DFZ) after oral administration. The administered radiocarbon [2'-14C]-deflAZacort), is rapidly and extensively absorbed into the general circulation in rat and man. The bioavailability in the dog is low.

ExcerptReferenceRelevance
" The administered radiocarbon [2'-14C]-deflazacort), is rapidly and extensively absorbed into the general circulation in rat and man, whereas the bioavailability in the dog is low."( Disposition of a new steroidal anti-inflammatory agent, deflazacort, in rat, dog and man.
Alessandro, A; Antonio, P; Giuseppe, B; Valeria, P, 1980
)
0.78
"The effect of high- and low-fat meals on the relative bioavailability of deflazacort tablets was investigated in 12 healthy, adult males who were administered 36 mg deflazacort under fasted and fed conditions in a crossover fashion."( The effect of food on the relative bioavailability of deflazacort.
Arumugham, T; Eller, M; Rao, N; Weir, S,
)
0.61
" Poorly soluble drugs present limited bioavailability due to their low solubility and dissolution rate and several strategies have been developed in order to find ways to improve them."( Dissolution enhancement of Deflazacort using hollow crystals prepared by antisolvent crystallization process.
Campos, CE; Capobianco, G; Cardoso, SG; Cuffini, SL; de Avillez, RR; Maurício, MH; Paulino, AS; Rauber, G, 2013
)
0.69
"Deflazacort (DFZ, a prodrug) is well absorbed and rapidly metabolized into the active metabolite 21-hydroxydeflazacort (21-OH DFZ) after oral administration."( [Pharmacokinetics of deflazacort tablets in healthy Chinese volunteers].
Ding, L; Ding, W; Li, WB; Lin, HD; Pan, H, 2014
)
2.16
" Since nitric oxide is a potent regulator of skeletal muscle metabolism, mass, function and regeneration, the loss of nitric oxide bioavailability is likely a key contributor to the chronic pathological wasting evident in Duchenne Muscular Dystrophy."( Therapeutic strategies to address neuronal nitric oxide synthase deficiency and the loss of nitric oxide bioavailability in Duchenne Muscular Dystrophy.
Hayes, A; Rybalka, E; Timpani, CA, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The transdermal DFZ-UENVs can achieve boosted bioavailability and may be suggested as an auspicious non-invasive alternative platform for oral route."( Response Surface Optimization of Ultra-Elastic Nanovesicles Loaded with Deflazacort Tailored for Transdermal Delivery: Accentuated Bioavailability and Anti-Inflammatory Efficacy.
Aboud, HM; Ali, AA; Eissa, EM; Hassan, AH, 2021
)
0.85

Dosage Studied

The aim of the study was to compare the long term effects of low dosage prednisolone or deflazacort treatment on bone mass in patients with polymyalgia rheumatica. There is a strong need for optimization of both specific type of glucocorticoid and the dosing regimen.

ExcerptRelevanceReference
" The second group of six patients received DFC initially followed by the PDN dosing regimen."( Effects of a new heterocyclic glucocorticoid, deflazacort (DFC), on the functions of lymphocytes from patients with rheumatoid arthritis (RA).
Imbimbo, B; Indiveri, F; Piccardo, C; Piovano, P; Scudeletti, M, 1987
)
0.53
" Steady state dosage between 1/2 and 3 tablets per day was individually adjusted according to the severity of the clinical symptoms."( Long-term therapy with the new glucocorticosteroid deflazacort in rheumatoid arthritis. Double-blind controlled randomized 12-months study against prednisone.
Eberhardt, R; Gross, W; Krüger, K; Reiter, W; Zwingers, T, 1994
)
0.54
"To compare the long term effects of low dosage prednisolone or deflazacort treatments on bone mass in patients with polymyalgia rheumatica."( Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: a double blind, prospective comparison between prednisolone and deflazacort.
Krogsgaard, MR; Lund, B; Thamsborg, G, 1996
)
0.73
" The results suggest that (i) DFC and PRED in equal anti-inflammatory dosage are similarly or equally efficient in slowing down the decline of muscle strength in DMD; (ii) benefits outweigh the side effects."( Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study.
Reitter, B, 1995
)
1.73
" However, a dose-response effect was seen only in the DFZ group."( In vitro improvement of chlorambucil-induced cytotoxicity by deflazacort and 6-methylprednisolone in B-cell chronic lymphocytic leukaemia.
Brugiatelli, M; Callea, I; Cartisano, G; Dattola, A; Irrera, G; Morabito, F; Rodinò, A, 1997
)
0.54
"The aim of the study was to compare the long term effects of low dosage prednisolone or deflazacort treatment on bone mass in patients with polymyalgia rheumatica."( [Bone loss during low dose glucocorticoid treatment in patients with polymyalgia rheumatica. A double-blind, prospective comparison between prednisolone and deflazacort].
Krogsgaard, MR; Lund, B; Thamsborg, G, 1997
)
0.72
" The interindividual variation was found to be mainly the time lag between dosage and maximum effect."( The effects of the glucocorticoids prednisolone, deflazacort and beclomethasone-dipropionate on the RM 3/1 macrophage in human peripheral blood.
Schmutzler, W; Zwadlo-Klarwasser, G, 1998
)
0.55
" Neither dosage nor glucocorticoid employed were modified during the study."( An open comparison of the diabetogenic effect of deflazacort and prednisone at a dosage ratio of 1.5 mg:1 mg.
Blanch Sancho, JJ; Carmona Martín, M; Navarro López, V; Puras Tellaeche, A; Sáez Barcelona, JA, 1999
)
0.56
" Cyclosporin A dosage and trough levels were not significantly different before and after steroid withdrawal."( Risk of steroid withdrawal in pediatric renal transplant patients with suspected steroid toxicity.
Förster, B; Jeck, N; Klaus, G; Konrad, M; Soergel, M, 2001
)
0.31
" Two class I trials examined the effect of lower dosage of prednisone (0."( Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
Ashwal, S; Baumbach, L; Connolly, A; Florence, J; Mathews, K; McDonald, C; Moxley, RT; Pandya, S; Sussman, M; Wade, C, 2005
)
0.33
" The employment of methotrexate attained decrease in the dosage of steroids temporarily."( [Treatment with nebulized lidocaine in steroid-dependent asthma].
de Paz Arranz, S; Fernández Parra, B; Herrera Mozo, I; Pérez Pimiento, A; Rodríguez Mosquera, M; Santaolalla Montoya, M,
)
0.13
" Correlation between daily corticosteroid dosage and remission time and factors relating to final visual acuity of <20/40 were studied."( Central serous chorioretinopathy after renal transplantation.
Byeon, SH; Kang, EC; Koh, HJ; Lee, CS; Lee, KS; Lee, SC, 2011
)
0.37
"Corticosteroid treatment is the standard of care in Duchenne muscular dystrophy (DMD), but the optimal age to initiate treatment and dosage pattern remain a matter of discussion."( Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up.
Armaroli, A; Cecconi, I; Cicognani, A; Ferlini, A; Franzoni, E; Gennari, M; Gnudi, S; Malaspina, E; Merlini, L; Talim, B, 2012
)
0.38
" There is a strong need for optimization of both specific type of glucocorticoid (eg, prednisone, vs deflazacort or others) and the dosing regimen."( Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy.
Bushby, K; Connor, EM; Damsker, J; Hoffman, EP; McCall, JM; Nagaraju, K; Reeves, E, 2012
)
0.59
" Differences in standards of care and dosing complicate interpretation of this finding, but stratification by PRED/DFZ might be considered in clinical trials."( Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.
Bello, L; Cnaan, A; Duong, T; Gordish-Dressman, H; Henricson, EK; Hoffman, EP; McDonald, CM; Morgenroth, LP, 2015
)
0.71
" Growth curve comparisons and linear mixed-effects modeling, adjusted for race/ethnicity and birth year, were used to evaluate growth and steroid treatment patterns (age at initiation, dosing interval, duration, cumulative dose)."( Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy.
Ciafaloni, E; DiGuiseppi, C; James, K; Lamb, MM; Ouyang, L; Pandya, S; Weitzenkamp, D; West, NA; Yang, M, 2016
)
0.43
" Daily prednisone dosing predicted lighter weight, but longer duration, and greater dosages predicted heavier weight."( Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy.
Ciafaloni, E; DiGuiseppi, C; James, K; Lamb, MM; Ouyang, L; Pandya, S; Weitzenkamp, D; West, NA; Yang, M, 2016
)
0.43
"We have extended the scope of this updated review to include comparisons of different corticosteroids and dosing regimens."( Corticosteroids for the treatment of Duchenne muscular dystrophy.
Brassington, R; Jichi, F; Kuntzer, T; Manzur, AY; Matthews, E, 2016
)
0.43
" Although daily glucocorticoid therapy has been shown to extend ambulatory function in DMD, less frequent dosing is often used because of side effect concerns."( Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment.
Jefferies, JL; McMahon, MA; Rutter, MM; Rybalsky, I; Sawnani, H; Shellenbarger, KC; Tian, C; Wong, BL, 2017
)
0.46
"Treatment of DMD patients with the corticosteroids prednisone or deflazacort remains the standard of care, and recent data shows that early treatment (as young as 5 months) with a weekend dosing regimen results in measurable improvement in motor outcomes."( Update in Duchenne and Becker muscular dystrophy.
Flanigan, KM; Waldrop, MA, 2019
)
0.75
" Thus, curtailment of daily dosing to eliminate dire sequelae in patients living longer into adulthood than ever before is recommended."( Glucocorticoid-Associated Demise of a Patient With Duchenne Muscular Dystrophy.
Bach, JR; Brahmsteadt, AE; Cespedes, L; Pierucci, P; Pishdad, R, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
corticosteroid hormoneAny of a class of steroid hormones that are produced in the adrenal cortex.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency1.94943.189029.884159.4836AID1224846
AR proteinHomo sapiens (human)Potency0.12330.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID743040; AID743042; AID743054
progesterone receptorHomo sapiens (human)Potency0.66510.000417.946075.1148AID1346784; AID1347036
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency13.80290.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.38060.000214.376460.0339AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency9.89720.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency8.76530.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency5.15670.001530.607315,848.9004AID1224849
pregnane X nuclear receptorHomo sapiens (human)Potency17.22890.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency2.58900.000229.305416,493.5996AID743069; AID743075; AID743079; AID743080; AID743091
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.07760.023723.228263.5986AID743222
aryl hydrocarbon receptorHomo sapiens (human)Potency28.79130.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.39450.001723.839378.1014AID743083
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency49.92410.057821.109761.2679AID1159526; AID1159528
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency15.84890.10009.191631.6228AID1346983
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency24.23380.000627.21521,122.0200AID743202; AID743219
Interferon betaHomo sapiens (human)Potency0.41910.00339.158239.8107AID1347407
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency24.50780.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency0.74740.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (48)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (88)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID409951Inhibition of human liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1292129Antiinflammatory activity in bradykinin-induced peritonitis Swiss mouse model assessed as decrease in total number of cells in pertonial cavity at 3 mg/kg, ip administered for 30 mins prior to bradykinin challenge2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Evaluation of the anti-inflammatory action of curcumin analog (DM1): Effect on iNOS and COX-2 gene expression and autophagy pathways.
AID1292117In vivo inhibition of myeloperoxidase activity in carrageenan-induced Swiss mouse peritonitis model at 1 to 100 mg/kg, ip administered prior to carrageenan challenge for 4hrs2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Evaluation of the anti-inflammatory action of curcumin analog (DM1): Effect on iNOS and COX-2 gene expression and autophagy pathways.
AID1292128In vivo inhibition of myeloperoxidase activity in bradykinin-induced Swiss mouse peritonitis model at 1 to 100 mg/kg, ip administered prior to bradykinin challenge for 4hrs2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Evaluation of the anti-inflammatory action of curcumin analog (DM1): Effect on iNOS and COX-2 gene expression and autophagy pathways.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID409949Inhibition of human liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1292110Antiinflammatory activity against substance-P-induced paw edema in Swiss mouse at 3 mg/kg, ip measured at 15 to 90 mins administered 30 mins prior to substance p-challenge by plethysmometric analysis2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Evaluation of the anti-inflammatory action of curcumin analog (DM1): Effect on iNOS and COX-2 gene expression and autophagy pathways.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1292104Antiinflammatory activity against carrageenan-induced paw edema in Swiss mouse at 3 mg/kg, ip measured at 15 to 90 mins administered 30 mins prior to carrageenan-challenge by plethysmometric analysis2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Evaluation of the anti-inflammatory action of curcumin analog (DM1): Effect on iNOS and COX-2 gene expression and autophagy pathways.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1292120Antiinflammatory activity in substance p-induced Swiss mouse peritonitis model assessed as decrease in total number of cells in pertonial cavity at 3 mg/kg, ip administered for 30 mins prior to substance-P challenge2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Evaluation of the anti-inflammatory action of curcumin analog (DM1): Effect on iNOS and COX-2 gene expression and autophagy pathways.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1292106Antiinflammatory activity against bradykinin-induced paw edema in Swiss mouse at 100 mg/kg, ip measured at 15 to 90 mins administered 30 mins prior to bradikynin-challenge by plethysmometric analysis2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Evaluation of the anti-inflammatory action of curcumin analog (DM1): Effect on iNOS and COX-2 gene expression and autophagy pathways.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1292112Antiinflammatory activity in carrageenan-induced Swiss mouse peritonitis model assessed as decrease in total number of cells in pertonial cavity at 3 mg/kg, ip administered for 4 hrs prior to carrageenan challenge2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Evaluation of the anti-inflammatory action of curcumin analog (DM1): Effect on iNOS and COX-2 gene expression and autophagy pathways.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347140qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347139qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347136qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347135qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347138qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347141qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347137qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (399)

TimeframeStudies, This Drug (%)All Drugs %
pre-199045 (11.28)18.7374
1990's130 (32.58)18.2507
2000's97 (24.31)29.6817
2010's103 (25.81)24.3611
2020's24 (6.02)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 103.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index103.53 (24.57)
Research Supply Index6.31 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index189.07 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (103.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials99 (21.90%)5.53%
Reviews47 (10.40%)6.00%
Case Studies111 (24.56%)4.05%
Observational2 (0.44%)0.25%
Other193 (42.70%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (18)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Registry of IgA Nephropathy in Chinese Children [NCT03015974]1,200 participants (Anticipated)Observational [Patient Registry]2016-01-31Recruiting
A Multi-center Study to Evaluate the Pharmacokinetics of 21-Desacetyldeflazacort and the Safety of Deflazacort After Oral Administration of Deflazacort Tablets to Children and Adolescent Subjects With Duchenne Muscular Dystrophy [NCT02251600]Phase 124 participants (Actual)Interventional2014-12-31Completed
A Single Dose Evaluation of the Effects of Moderate (Child-Pugh Grade B) Hepatic Impairment on Deflazacort Pharmacokinetics [NCT02286609]Phase 116 participants (Actual)Interventional2014-12-31Completed
A 52-Week Phase 3B Randomized Open-Label Study Evaluating the Safety and Pharmacokinetics of Emflaza® (Deflazacort) Compared to a Comparable Natural History Control Group in Males Aged ≥2 to <5 Years With Duchenne Muscular Dystrophy (DMD) Followed by a 52 [NCT03642145]Phase 30 participants (Actual)Interventional2018-10-31Withdrawn(stopped due to Study is no longer necessary given the safety and efficacy of emflaza in this age range has already been established after review of already available data.)
A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics [NCT02286622]Phase 116 participants (Actual)Interventional2014-12-31Completed
An Open-Label, Multi-Center, Long-Term Extension Study to Evaluate the Safety and Tolerability of Orally Administrated Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy [NCT02295748]Phase 124 participants (Actual)Interventional2014-12-31Completed
A Multicenter Open-Label Study on the Safety and Efficacy of Deflazacort (Emflaza) in Subjects With Limb-Girdle Muscular Dystrophy 2I (LGMD2I) [NCT03783923]Phase 311 participants (Actual)Interventional2019-10-31Terminated(stopped due to The study was terminated early due to low enrollment and missing efficacy assessment data due to missed visits related to COVID-19.)
A Single-Dose, Single-Center, Randomized, Five Period Crossover Study Comparing Food Effect and Bioavailability of Deflazacort Formulations in Healthy Volunteers [NCT02485431]Phase 145 participants (Actual)Interventional2015-06-30Completed
Evaluation of the Effects of Pre-operative Deflazacort on Post-operative Pain, Edema and Trismus in Impacted Lower Third Molar Surgery [NCT04365088]Phase 435 participants (Actual)Interventional2018-12-15Active, not recruiting
A Randomized Controlled Trial of Deflazacort vs. Prednisolone in Acute-stage Allergic Bronchopulmonary Aspergillosis [NCT04227483]Phase 2/Phase 3150 participants (Actual)Interventional2020-01-15Active, not recruiting
An Open Label, Expanded Access Protocol Intended to Provide Treatment With MP-104 (Deflazacort) to U.S. Children, Adolescents, and/or Adults With Duchenne Muscular Dystrophy [NCT02592941]0 participants Expanded AccessApproved for marketing
A Phase 1, Open-Label Study to Evaluate CYP3A4 Drug-Drug Interactions of Edasalonexent in Healthy Adult Subjects [NCT04543370]Phase 126 participants (Actual)Interventional2020-08-08Completed
Deflazacort in Dysferlinopathies (LGMD2B/MM) - a Double Blind, Placebo-controlled Clinical Study [NCT00527228]Phase 2/Phase 325 participants (Actual)Interventional2003-09-30Completed
A Phase 1, Open-Label, 2-Arm, Fixed-Sequence Study to Evaluate the Potential Effects of Multiple Doses of Rifampin (CYP3A4 Inducer) and Clarithromycin (CYP3A4 Inhibitor) on the Single Dose Pharmacokinetics of Deflazacort in Healthy Subjects [NCT02286635]Phase 158 participants (Actual)Interventional2014-11-30Completed
Kidney Graft Function Under the Immunosuppression Strategies With Low Dose of Neoral®(Cyclosporine) and Standard Dose of Myfortic®(Enteric-Coated Mycophenolate Sodium) vs. With Conventional Dose of Neoral®(Cyclosporine) and Reduced Dose of Myfortic®(Enter [NCT01817322]Phase 4140 participants (Actual)Interventional2011-06-30Completed
Characterization of Heart Rate Variability in Individuals With Duchenne Muscular Dystrophy - Influence of Corticosteroids and Betablockers [NCT04740554]40 participants (Actual)Observational2013-03-01Completed
Study of the Excretion of Orally Administered Corticosteroids for the Improval of the Detection of Said Substances in Anti-doping Controls [NCT04791345]Phase 150 participants (Anticipated)Interventional2021-02-26Recruiting
Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen [NCT01603407]Phase 3196 participants (Actual)Interventional2013-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01603407 (17) [back to overview]6 Minute Walk Test
NCT01603407 (17) [back to overview]Forced Vital Capacity
NCT01603407 (17) [back to overview]Fractional Shortening Percent
NCT01603407 (17) [back to overview]Heart Rate
NCT01603407 (17) [back to overview]Left Ventricular Ejection Fraction Percent
NCT01603407 (17) [back to overview]North Star Ambulatory Assessment (NSAA) Score
NCT01603407 (17) [back to overview]Number of Participants Who Tolerated the Regimen
NCT01603407 (17) [back to overview]Participant Body Mass Index
NCT01603407 (17) [back to overview]Participant Height
NCT01603407 (17) [back to overview]Participant Weight
NCT01603407 (17) [back to overview]PR Interval
NCT01603407 (17) [back to overview]Quality of Life - Parent
NCT01603407 (17) [back to overview]Quality of Life- Child
NCT01603407 (17) [back to overview]Range of Motion (Goniometry) of Left Ankle
NCT01603407 (17) [back to overview]Range of Motion (Goniometry) of Right Ankle
NCT01603407 (17) [back to overview]Rise From the Floor Velocity
NCT01603407 (17) [back to overview]Treatment Satisfaction Questionnaire for Medication (TSQM) Global Satisfaction With Treatment Score
NCT03783923 (11) [back to overview]Number of Participants With Adverse Events (AEs)
NCT03783923 (11) [back to overview]Area Under the Concentration Curve From Time Zero to Infinity (AUC0-inf) of 21-desacetyl Deflazacort and 6β-hydroxy-21-desacetyl Deflazacort
NCT03783923 (11) [back to overview]Area Under the Concentration Curve From Time Zero to t (AUC0-t) of 21-desacetyl Deflazacort and 6β-hydroxy-21-desacetyl Deflazacort
NCT03783923 (11) [back to overview]Change From Baseline in 2-Minute Walk Test After 26 Weeks of Treatment of Deflazacort
NCT03783923 (11) [back to overview]Change From Baseline in Time to Climb 4 Stairs After 26 Weeks of Treatment With Deflazacort
NCT03783923 (11) [back to overview]Change From Baseline in Time to Descend 4 Stairs After 26 Weeks of Treatment With Deflazacort
NCT03783923 (11) [back to overview]Change From Baseline in Time to Run/Walk 10 Meters After 26 Weeks of Treatment With Deflazacort
NCT03783923 (11) [back to overview]Change From Baseline in Time to up and go After 26 Weeks of Treatment With Deflazacort
NCT03783923 (11) [back to overview]Half-Life (t1/2) of 21-desacetyl Deflazacort and 6β-hydroxy-21-desacetyl Deflazacort
NCT03783923 (11) [back to overview]Maximum Observed Plasma Concentration (Cmax) of 21-desacetyl Deflazacort and 6β-hydroxy-21-desacetyl Deflazacort
NCT03783923 (11) [back to overview]Time to Reach Cmax (Tmax) of 21-desacetyl Deflazacort and 6β-hydroxy-21-desacetyl Deflazacort

6 Minute Walk Test

Measures the total distance walked in 6 minutes averaged over all post-baseline follow-up visits through Month 36. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits

Interventionmeters (Least Squares Mean)
Daily Prednisone384.95
Daily Deflazacort384.17
Intermittent Prednisone346.81

[back to top]

Forced Vital Capacity

Forced vital capacity was measured during a spirometry test. Forced expiratory volume (FEV) measures how much air a person can exhale during a forced breath. Forced vital capacity (FVC) is the total amount of air exhaled during the FEV test. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits

Interventionliters (Least Squares Mean)
Daily Prednisone1.4
Daily Deflazacort1.4
Intermittent Prednisone1.5

[back to top]

Fractional Shortening Percent

Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months

Interventionpercentage of fractional shortening (Least Squares Mean)
Daily Prednisone33.74
Daily Deflazacort34.01
Intermittent Prednisone34.33

[back to top]

Heart Rate

Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months

Interventionbpm (Least Squares Mean)
Daily Prednisone94.10
Daily Deflazacort93.52
Intermittent Prednisone91.65

[back to top]

Left Ventricular Ejection Fraction Percent

Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months

Interventionpercentage of ejection fraction (Least Squares Mean)
Daily Prednisone61.88
Daily Deflazacort62.65
Intermittent Prednisone62.45

[back to top]

North Star Ambulatory Assessment (NSAA) Score

"The North Star Ambulatory Assessment (NSAA) is a 17-item rating scale that is used to measure functional motor abilities in ambulant children with Duchenne Muscular Dystrophy (DMD). It is usually used to monitor the progression of the disease and treatment effects.~The activities are graded as follows:~2 - Normal - no obvious modification of activity~1 - Modified method but achieves goal independent of physical assistance from another 0 - Unable to achieve independently This scale is ordinal with 34 as the maximum score indicating fully-independent function." (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits

Interventionscore on a scale (Least Squares Mean)
Daily Prednisone23.7
Daily Deflazacort24.0
Intermittent Prednisone20.7

[back to top]

Number of Participants Who Tolerated the Regimen

The number of participants who completed 36 months of follow-up on the originally assigned dosage (for weight) of study medication. (NCT01603407)
Timeframe: 3 years

InterventionParticipants (Count of Participants)
Daily Prednisone36
Daily Deflazacort36
Intermittent Prednisone37

[back to top]

Participant Body Mass Index

(NCT01603407)
Timeframe: 36 months

Interventionkilograms/square meter (Least Squares Mean)
Daily Prednisone18.9
Daily Deflazacort18.3
Intermittent Prednisone18.1

[back to top]

Participant Height

(NCT01603407)
Timeframe: 36 months

Interventioncentimeters (Least Squares Mean)
Daily Prednisone116.8
Daily Deflazacort115.3
Intermittent Prednisone119.9

[back to top]

Participant Weight

(NCT01603407)
Timeframe: 36 months

Interventionkilograms (Least Squares Mean)
Daily Prednisone26.3
Daily Deflazacort24.9
Intermittent Prednisone26.3

[back to top]

PR Interval

Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months

Interventionmilliseconds (Least Squares Mean)
Daily Prednisone115.59
Daily Deflazacort116.87
Intermittent Prednisone117.90

[back to top]

Quality of Life - Parent

Quality of life was measured by parent/guardian self-report for all children utilizing the PEDSQL measurement tool. This is a 23-question tool. Scores can range from 0 to 100, with higher scores indicating better quality of life for the child. (NCT01603407)
Timeframe: Average of Months 12, 24, and 36 visits

Interventionscore on a scale (Least Squares Mean)
Daily Prednisone64.88
Daily Deflazacort63.71
Intermittent Prednisone61.33

[back to top]

Quality of Life- Child

Quality of life was measured by child self-report in children age 5 and older utilizing the PEDSQL measurement tool. This is a 23-question tool. Scores can range from 0 to 100, with higher scores indicating better quality of life. (NCT01603407)
Timeframe: Average of Months 12, 24, and 36 visits

Interventionscore on a scale (Least Squares Mean)
Daily Prednisone67.39
Daily Deflazacort64.96
Intermittent Prednisone65.07

[back to top]

Range of Motion (Goniometry) of Left Ankle

Range of motion at the ankle joint in dorsiflexion measured in degrees from plantigrade averaged over all post-baseline visits. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits

Interventiondegrees (Mean)
Daily Prednisone4.39
Daily Deflazacort3.29
Intermittent Prednisone2.67

[back to top]

Range of Motion (Goniometry) of Right Ankle

Range of motion at the ankle joint in dorsiflexion measured in degrees from plantigrade averaged over all post-baseline visits. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits

Interventiondegrees (Mean)
Daily Prednisone4.05
Daily Deflazacort2.81
Intermittent Prednisone2.29

[back to top]

Rise From the Floor Velocity

Reciprocal of time to rise from the floor (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits

Interventionrise/sec (Least Squares Mean)
Daily Prednisone0.24
Daily Deflazacort0.24
Intermittent Prednisone0.18

[back to top]

Treatment Satisfaction Questionnaire for Medication (TSQM) Global Satisfaction With Treatment Score

The TSQM Global Satisfaction with Treatment is a 14-item questionnaire that ranges from 0 - 100 with higher scores indicating better outcomes. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits

Interventionscore on a scale (Least Squares Mean)
Daily Prednisone71.2
Daily Deflazacort67.8
Intermittent Prednisone65.1

[back to top]

Number of Participants With Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'. AEs were summarized separately for Stage 1 and for the overall ataluren experience. (NCT03783923)
Timeframe: Baseline up to Week 52

InterventionParticipants (Count of Participants)
Deflazacort5

[back to top]

Area Under the Concentration Curve From Time Zero to Infinity (AUC0-inf) of 21-desacetyl Deflazacort and 6β-hydroxy-21-desacetyl Deflazacort

(NCT03783923)
Timeframe: Pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose at Baseline and Week 13

Interventionng*hr/mL (Mean)
21-desacetyl deflazacort: Baseline6β-hydroxy-21-desacetyl deflazacort: Week 1
Deflazacort423.6520.3

[back to top]

Area Under the Concentration Curve From Time Zero to t (AUC0-t) of 21-desacetyl Deflazacort and 6β-hydroxy-21-desacetyl Deflazacort

(NCT03783923)
Timeframe: Pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose at Baseline and Week 13

Interventionnanograms (ng)*hour (hr)/milliliter (mL) (Mean)
21-desacetyl deflazacort: Baseline21-desacetyl deflazacort: Week 136β-hydroxy-21-desacetyl deflazacort: Week 16β-hydroxy-21-desacetyl deflazacort: Week 13
Deflazacort401.1365.6418.2515.3

[back to top]

Change From Baseline in 2-Minute Walk Test After 26 Weeks of Treatment of Deflazacort

(NCT03783923)
Timeframe: Baseline, Week 26

Interventionmeters (Mean)
BaselineChange at Week 26
Deflazacort135.42.0

[back to top]

Change From Baseline in Time to Climb 4 Stairs After 26 Weeks of Treatment With Deflazacort

(NCT03783923)
Timeframe: Baseline, Week 26

Interventionseconds (Mean)
BaselineChange at Week 26
Deflazacort5.476-0.200

[back to top]

Change From Baseline in Time to Descend 4 Stairs After 26 Weeks of Treatment With Deflazacort

(NCT03783923)
Timeframe: Baseline, Week 26

Interventionseconds (Mean)
BaselineChange at Week 26
Deflazacort3.660.10

[back to top]

Change From Baseline in Time to Run/Walk 10 Meters After 26 Weeks of Treatment With Deflazacort

(NCT03783923)
Timeframe: Baseline, Week 26

Interventionseconds (Mean)
BaselineChange at Week 26
Deflazacort8.53-0.40

[back to top]

Change From Baseline in Time to up and go After 26 Weeks of Treatment With Deflazacort

(NCT03783923)
Timeframe: Baseline, Week 26

Interventionseconds (Mean)
BaselineChange at Week 26
Deflazacort11.939.70

[back to top]

Half-Life (t1/2) of 21-desacetyl Deflazacort and 6β-hydroxy-21-desacetyl Deflazacort

(NCT03783923)
Timeframe: Pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose at Baseline and Week 13

Interventionhr (Mean)
21-desacetyl deflazacort: Baseline21-desacetyl deflazacort: Week 136β-hydroxy-21-desacetyl deflazacort: Week 16β-hydroxy-21-desacetyl deflazacort: Week 13
Deflazacort1.1741.2352.3581.95

[back to top]

Maximum Observed Plasma Concentration (Cmax) of 21-desacetyl Deflazacort and 6β-hydroxy-21-desacetyl Deflazacort

(NCT03783923)
Timeframe: Pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose at Baseline and Week 13

Interventionng/mL (Mean)
21-desacetyl deflazacort: Baseline21-desacetyl deflazacort: Week 136β-hydroxy-21-desacetyl deflazacort: Week 16β-hydroxy-21-desacetyl deflazacort: Week 13
Deflazacort184.8171.0135.8162.0

[back to top]

Time to Reach Cmax (Tmax) of 21-desacetyl Deflazacort and 6β-hydroxy-21-desacetyl Deflazacort

(NCT03783923)
Timeframe: Pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose at Baseline and Week 13

Interventionhr (Median)
21-desacetyl deflazacort: Baseline21-desacetyl deflazacort: Week 136β-hydroxy-21-desacetyl deflazacort: Week 16β-hydroxy-21-desacetyl deflazacort: Week 13
Deflazacort0.9920.5251.0001.550

[back to top]